LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Incyte Corp

Închisă

SectorSănătate

68.78 2.34

Rezumat

Modificarea prețului

24h

Curent

Minim

67.05

Maxim

68.95

Indicatori cheie

By Trading Economics

Venit

-43M

158M

Vânzări

-126M

1.1B

P/E

Medie Sector

326.55

51.198

EPS

1.16

Marjă de profit

15.025

Angajați

2,617

EBITDA

-80M

257M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+5.22% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-3.4B

13B

Deschiderea anterioară

66.44

Închiderea anterioară

68.78

Sentimentul știrilor

By Acuity

20%

80%

46 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2025, 14:31 UTC

Câștiguri

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 iun. 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 iun. 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 iun. 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 iun. 2025, 16:35 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:34 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 iun. 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 iun. 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 iun. 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 iun. 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 iun. 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 iun. 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 iun. 2025, 14:12 UTC

Câștiguri

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 iun. 2025, 14:09 UTC

Câștiguri

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

5.22% sus

Prognoză pe 12 luni

Medie 72.36 USD  5.22%

Maxim 89 USD

Minim 52 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

6

Cumpărare

12

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

46 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation